Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Edderd who wrote (13522)	8/17/1998 8:44:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

Edderd, My understanding is that it is easy to manufacture but as with most pharmaceuticals often the most difficult step in the manufacturing process is obtaining purity and consistency of dosing. The consistency of dosing is usually the most difficult and costly part to perfect. I do not know what type of expertise/reputation the Indians have for manufacturing. But if they have poor quality control and have inconsistant batch processing then some pills may have too little effective ingredient thus making the dose ineffective while too much drug can actually increase the risks of severe hypotension.